Vidarabine and 2-Deoxycoformycin as Antileukemic Agents Against Monocytic Leukemia

References

• Gelmon K.A., Eisenhauer E.A., Harris A.L., Ratain M.J. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?. J Natl Cancer Inst 1999).; 91: 1281–1287
   PubMed Web of Science ®Google Scholar
• Gibbs J.B., Oliff A., Kohl N.E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994; 77: 175–178
   PubMed Web of Science ®Google Scholar
• Kohl N.E., Wilson F.R., Mosser S.D., Giuliani E., deSolms S.J., Conner M.W., Anthony N.J., Holtz W.J., Gomez R.P., Lee T.-J., Smith R.L., Graham S.L., Hartman G.D., Gibbs J.B., Oliff A. Farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 1994; 91: 9141–9145
   PubMed Web of Science ®Google Scholar
• Honma Y., Okabe-Kado J., Hozumi M., Uehara Y., Mizuno S. Induction of erythroid differentiation of K562 leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res 1989; 49: 331–334
   PubMed Web of Science ®Google Scholar
• Honma Y, Hozumi M. Control of growth and differentiation of Philadelphia chromosome-positive leukemia cells by tyrosine kinase inhibitors. In Current Perspectives on Molecular & Cellular Oncology, vol. 1992; 1, edited by D.A. Spandidos, pp 153-173, London: JAI Press
   Google Scholar
• Honma Y, Matsuo Y, Hayashi Y, Omura S. Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor. Int J Cancer 1995; 60: 685–688
   PubMed Web of Science ®Google Scholar
• Huang M., Ye Y, Chen S., Chai J., Lu J., Lin Z., Gu L., Wang Z. Use of all-transretinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Warrell R.P., Jr., deThe H., Wang Z.-Y, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Makishima M., Umesono K., Shudo K., Naoe T., Kishi K., Honma Y. Induction of differentiation in acute promyelocytic leukemia cells by 9-cis retinoic acid α-tocopherol ester (9-cis tretinoin tocopheril). Blood 1998).; 19: 4715–4726
   Google Scholar
• Heim S., Mitelman E. Cancer Cytogenetics, 2nd edn. Wiley, New York 1995; 69–140
   Google Scholar
• Odom L.F., Lampkin B.C., Tannous R., Buckley J.D., Hammond G.D. Acute monoblastic leukemia: A unique subtype-A review from the children cancer study group. Leuk Res 1990; 14: 1–10
   PubMed Web of Science ®Google Scholar
• Fenaux P., Vanhaesbroucke C., Estienne M.H., Preud'homme C., Pagniez D., Facon X, Millot E, Bauters F. Acute monocytic leukaemia in adults: Treatment and prognosis in 99 cases. Br J Haematol 1990; 75: 41–48
   PubMed Web of Science ®Google Scholar
• Fung H., Shepherd J.D., Naiman S.C., Barnett M.J., Reece D.E., Horsman D.E., Nantel S.H., Sutherland H.J., Spinelli J.J., Klingemann H.-G., Philips G.L. Acute monocytic leukemia: A single institution experience. Leuk Lymphoma 1995; 19: 259–265
   PubMed Web of Science ®Google Scholar
• Yamada K., Hino K., Tomoyasu S., Honma Y, Tsuruoka N. Enhancement by bufalin of retinoic acid-induced differentiation of acute promyelocytic leukemia cells in primary culture. Leuk Res 1998; 22: 589–595
   PubMed Web of Science ®Google Scholar
• Tkachuk D.C., Kohler S., Cleary M.L. Involvement of a homolog of Drosophila thorax by 11q23 chromosomal translocations in acute leukemia. Cell 1992; 71: 691–700
   PubMed Web of Science ®Google Scholar
• Kraut E.H., Grever M.R., Bouroncle B.A. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 1994; 84: 4061–4063
   PubMed Web of Science ®Google Scholar
• Yamaguchi K., Yul L.S., Oda X, Maeda X, Ishii Y, Fujita M., Kagiyama K., Nagai S., Suzuki K., Takatsuki K. Clinical consequences of 2′-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia. Leuk Res 1986).; 10: 989–993
   PubMed Web of Science ®Google Scholar
• Blick M., Lepe-Zuniga J.L., Doig R., Quesada J.R. Durable complete remissions after 2′-deoxycoformy-cin treatment in patients with hairy cell leukemia resistant to interferon alpha. Am J Hematol 1990; 33: 205–209
   PubMed Web of Science ®Google Scholar
• Foon K.A., Rai K.R., Gale R.P. Chronic lymphocytic leukemia: New insights into biology and therapy. Ann Intern Med 1990; 113: 525–539
   PubMed Web of Science ®Google Scholar
• Cassileth PA., Cheuvart B., Speirs A.S.D., Harrington D.P., Cummings F.J., Neiman R.S., Bennett J.M., O'Connell M.J. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991; 9: 243–246
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocytic count. J Clin Oncol 1993; 11: 679–689
   PubMed Web of Science ®Google Scholar
• O'Brien S., Kantarjian H., Beran M., Smith X, Roller C., Estey E., Robertson L.E., Lerner S., Keating M. Results of fludarabine- and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695–1700
   PubMed Web of Science ®Google Scholar
• Kantarjian H.M., Alexanian R., Koller C.A., Kurzrock R., Keating M.J. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990; 75: 1928–1931
   PubMed Web of Science ®Google Scholar
• Montgomery J.A., Clayton S.D., Shortnacy A.X, Hewson K. An improved procedure for the preparation of 9- β-D-arabinofuranosyl-2-fluoroadenine. J Heterocyclic Chem 1979; 16: 157–160
   Web of Science ®Google Scholar
• Brockman R.W., Cheng Y.-C., Schabel F.M., Montgomery J.A. Metabolism and chemotherapeutic activity of 9- β-D-arabinofuranosyl-2-fluoroadenineagainst murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 1980; 40: 3610–3615
   PubMed Web of Science ®Google Scholar
• Simon L.N., Bauer R.J., Tolman R.L., Robins R.K. Calf intestine adenosine deaminase. Substrate specificity. Biochemistry 1970; 9: 573–577
   PubMed Web of Science ®Google Scholar
• Niitsu N., Honma Y. Adenosine analogs as possible differentiation-inducing agents against acute myeloid leukemia. Leuk Lymphoma 1999; 34: 261–271
   PubMed Web of Science ®Google Scholar
• Niitsu N., Umeda M., Honma Y. Induction of differentiation of human myeloid leukemia cells by 2′-deoxy-cofoBiochrmycin in combination with 2′-deoxyadenosine. Biochem Biophys Res Commun 1997; 238: 100–106
   PubMed Web of Science ®Google Scholar
• Niitsu N., Yamaguchi Y., Umeda M., Honma Y. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2′-deoxycoformycin and 2′-deoxyadenosine: Association with dATP-dependent activation of caspase-3. Blood 1998; 92: 3368–3375
   PubMed Web of Science ®Google Scholar
• Niitsu N., Yamamoto-Yamaguchi Y., Kasukabe T., Okabe-Kado J., Umeda M., Honma Y. Antileukemic efficacy of 2′-deoxycoformycin in monocytic leukemia. Jpn J Clin Hematol 1998; 39, 905 (Abstract)
   PubMedGoogle Scholar
• Niitsu N., Umeda M, Honma Y. Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs. Leuk Res 2000; 24: 1–9
   PubMed Web of Science ®Google Scholar
• Miller R.L., Admaczyk D.L., Miller W.H., Koszalka G.W., Rideout J.L., Beacham L.M., Chao E.Y, Haggerty J.J., Krenitsky T.A., Elion G.B. Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity. J Biol Chem 1979).; 254: 2346–2352
   PubMed Web of Science ®Google Scholar
• Honma Y, Hozumi M., Abe E., Konno K., Fukushima M., Hata S., Nishii Y, DeLuca H.F. 1α,25-Dihydroxyvitamin D3 and 1α-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 1983; 80: 201–204
   PubMed Web of Science ®Google Scholar
• Koeffler H.P., Hirji K., Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemia cells. Cancer Treat Rep 1985; 69: 1399–1470, The Southern California Leukemia Group.
   PubMedGoogle Scholar
• Enari M., Hug M., Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375: 78–81
   PubMed Web of Science ®Google Scholar
• Feraandes-Alnemri T., Litwack G., Alnemri E.S. CPP32, a novel human apoptotic protein with homologue to Caenorhabditis elegans cell death protein ced-3 and mammalian interleukin-1β-converting enzyme. J Biol Chem 1994; 269: 30761–30764
   PubMed Web of Science ®Google Scholar
• Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86: 147–157
   PubMed Web of Science ®Google Scholar
• Nicholson W.D., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y, Griffin P.R., Labelle M., Lazebnik Y.A., Munday N.A., Raju S.M., Smulsom M.E., Yamin T.T., Yu V.L., Miller D.K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37–43
   PubMed Web of Science ®Google Scholar
• Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmadt M., Alnemri E.S., Wang X. Cytochrome C and dATP-dependent formation of Apaf-1/cas-pase-9 complex initiates an apoptotic protease cascade. Cell 1997).; 91: 479–489
   Google Scholar
• Martins L.M., Mesner P.W., Kottke T.J., Basai G.S., Sinha S., Tung J.S., Svingen P.A., Madden B.J., Takahashi A., McCormick D.J., Earnshaw W.C., Kaufmann S.H. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90: 4283–4296
   PubMed Web of Science ®Google Scholar
• Williams G.T., Smith C.A. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777–779
   PubMed Web of Science ®Google Scholar
• Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Checkpoints of dueling dimers foil death wishes. Cell 1994; 79: 189–192
   PubMed Web of Science ®Google Scholar
• Miser J.S., Roloff J., Blatt J., Reaman G.H., Krailo M.D., Hammond G.D. Lack of significant activity of 2′-deoxycoformycin alone or in combination with adenine arabinoside in relapsed childhood acute lymphoblastic leukemia. Am J Clin Oncol (CCT) 1992; 15: 490–493
   PubMed Web of Science ®Google Scholar
• Malspeis L., Weinrib A.B., Staubus A.E., Grever M.R., Balcerzak S.P., Neidhart J.A. Clinical pharmacokinetics of 2′-deoxycoformycin. Cancer Treat Symp 1984; 2: 7–15
   Google Scholar
• Kinkel A.W., Buchanan R.A. Human pharmacology. Adenine Arabinoside: An Antiviral Agent, D. Pavan-Langston, R.A. Buchanan, C.A. Alford. Raven Press, New York 1975; 197–204
   Google Scholar
• Agarwal R.P. Pharmacology of 2′-deoxycoformycin and vidarabine. Cancer Treat Symp 1984; 2: 17–22
   Google Scholar
• Parker W.B., Bapat A.R., Shen J.-X., Townsend A.J., Cheng Y.-C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerase, DNA pri-mase, and ribonucleotide reductase. Mol Pharmacol 1988).; 34: 485–491
   PubMed Web of Science ®Google Scholar